The estimated Net Worth of Brendan P.Eckelman Living T... is at least 39.8 百万$ dollars as of 1 March 2023. Brendan T owns over 40,000 units of Inhibrx stock worth over 30,533,295$ and over the last 4 years Brendan sold INBX stock worth over 9,232,856$.
Sign up
Brendan T INBX stock SEC Form 4 insiders trading
Brendan has made over 12 trades of the Inhibrx stock since 2021, according to the Form 4 filled with the SEC. Most recently Brendan sold 40,000 units of INBX stock worth 968,400$ on 1 March 2023.
The largest trade Brendan's ever made was selling 40,000 units of Inhibrx stock on 1 March 2023 worth over 968,400$. On average, Brendan trades about 28,171 units every 53 days since 2021. As of 1 March 2023 Brendan still owns at least 2,035,553 units of Inhibrx stock.
You can see the complete history of Brendan T stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Inhibrx
Over the last 4 years, insiders at Inhibrx have traded over 27,711,393$ worth of Inhibrx stock and bought 2,717,119 units worth 64,845,764$ . The most active insiders traders include Global Investors Lp Viking ...、Capital Management, L.P.Kol...、Global Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of 1,598,400$. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth 671,000$.
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
What does Inhibrx's logo look like?
Complete history of Brendan T stock trades at Inhibrx
Inhibrx executives and stock owners
Inhibrx executives and other stock owners filed with the SEC include:
-
Mark Paul Lappe,
Founder, Chairman, Pres & CEO -
Dr. Klaus W. Wagner,
Chief Medical Officer & Exec. VP -
Dr. Brendan P. Eckelman Ph.D.,
Founder, Chief Scientific Officer & Exec. VP of Corp. Strategy -
Kelly Devine Deck B.S., CPA, M.S.,
Chief Financial Officer -
Klaus Wagner,
Executive Vice President, Chief Medical Officer -
Kelly Deck,
Chief Financial Officer -
Quinn Deveraux,
Co-Founder, Executive Vice President - Early Research -
Brendan Eckelman,
Co-Founder, Executive Vice President - Corporate Strategy, Chief Scientific Officer -
Mark Lappe,
Chairman of the Board, Chief Executive Officer, Founder -
David Matly M.B.A.,
Exec. VP & Chief Commercial Officer -
Jeffrey J. Jensen,
Exec. VP of Clinical Operations -
Leah Pollema J.D.,
VP, Corp. Sec. & Gen. Counsel -
Dr. Ashraf Amanullah,
Exec. VP & Chief Technical Operations Officer -
Capital Management, L.P.Kol...,
-
Brendan P. Eckelman,
Chief Scientific Officer -
Jon Faiz Kayyem,
Director -
Global Investors Lp Viking ...,
-
Kristiina Md Vuori,
Director -
Douglas Forsyth,
Director -
Kimberly Manhard,
Director -
Global Investors Lp Viking ...,
-
Inc. Inhibrx,,
-
Mark Lappe,
Chief Executive Officer